Valuation: Akeso, Inc.

Capitalization 11TCr 13TCr 1.62TCr 1.38TCr 1.28TCr 1.2TCr 2.24TCr 1,51700Cr 2.3TCr 15TCr 5.88TCr 72TCr 6.08TCr 5.95TCr 2,58900Cr P/E ratio 2025
-82.6x
P/E ratio 2026 * 449x
Enterprise value 11TCr 12TCr 1.58TCr 1.35TCr 1.24TCr 1.17TCr 2.18TCr 1,47600Cr 2.23TCr 15TCr 5.72TCr 70TCr 5.92TCr 5.79TCr 2,51800Cr EV / Sales 2025
29.2x
EV / Sales 2026 * 20.2x
Free-Float
74.46%
Yield 2025 *
-
Yield 2026 * -
1 day-0.29%
1 week-1.92%
Current month+5.84%
1 month+24.03%
3 months+9.28%
6 months+7.66%
Current year+21.95%
1 week 132.8
Extreme 132.8
142
1 month 108.9
Extreme 108.9
142
Current year 93.65
Extreme 93.65
142
1 year 73.1
Extreme 73.1
179
3 years 26.45
Extreme 26.45
179
5 years 11.5
Extreme 11.5
179
10 years 11.5
Extreme 11.5
179
Manager TitleAgeSince
Corporate Officer/Principal 50 16/11/2019
Corporate Officer/Principal 57 16/11/2019
Chief Tech/Sci/R&D Officer 58 16/11/2019
Director TitleAgeSince
Chairman 59 19/03/2012
Director/Board Member 58 16/11/2019
Director/Board Member 57 16/11/2019
Change 5d. change 1-year change 3-years change Capi.($)
-0.29%-1.92%+67.64%+203.86% 1.63TCr
-0.73%+4.60%+32.64%+97.15% 4.98TCr
-0.58%+5.72%+102.90%+27.47% 4.7TCr
-2.37%-7.73%+112.78%+776.68% 3.34TCr
+1.26%+5.94%-5.51%-25.41% 2.42TCr
-1.73%+0.86%+76.93%-29.37% 1.9TCr
+0.31%+2.51%+40.93%-34.28% 1.73TCr
+1.83%+7.17%-23.34%+1,151.88% 1.53TCr
-1.18%-3.24%+61.32% - 1.47TCr
+1.17%-1.54%+63.09%+119.28% 1.19TCr
Average -0.23%+0.70%+52.94%+254.14% 2.49TCr
Weighted average by Cap. -0.48%+1.68%+58.94%+224.91%

Financials

2025 2026 *
Net sales 328.72Cr 376.95Cr 48Cr 41Cr 38Cr 36Cr 66Cr 4.51TCr 68Cr 444.01Cr 174.56Cr 2.15TCr 180.61Cr 176.78Cr 7.69TCr 518.94Cr 595.07Cr 76Cr 65Cr 60Cr 56Cr 104.95Cr 7.11TCr 107.61Cr 700.94Cr 275.57Cr 3.4TCr 285.12Cr 279.07Cr 12TCr
Net income -27Cr -31Cr -3.96Cr -3.38Cr -3.12Cr -2.95Cr -5.47Cr -371.02Cr -5.61Cr -37Cr -14Cr -177.19Cr -15Cr -15Cr -632.93Cr 24Cr 27Cr 3.5Cr 2.99Cr 2.75Cr 2.6Cr 4.83Cr 327.35Cr 4.95Cr 32Cr 13Cr 156.33Cr 13Cr 13Cr 558.42Cr
Net Debt -302.55Cr -346.94Cr -44Cr -38Cr -35Cr -33Cr -61Cr -4.15TCr -63Cr -408.66Cr -160.66Cr -1.98TCr -166.23Cr -162.7Cr -7.08TCr -561.89Cr -644.32Cr -82Cr -70Cr -65Cr -61Cr -113.63Cr -7.7TCr -116.52Cr -758.96Cr -298.38Cr -3.68TCr -308.72Cr -302.17Cr -13TCr
Logo Akeso, Inc.
Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.
Employees
3,761
Date Price Change Volume
13/26/13 137.80 $ -0.29% 55,68,206
10/26/10 138.20 $ +1.99% 42,27,095
09/26/09 135.50 $ -1.45% 56,49,136
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
120.17CNY
Average target price
151.36CNY
Spread / Average Target
+25.95%

Quarterly revenue - Rate of surprise